Sesen Bio Inc To Discuss Pending Merger With Carisma Therapeutics Transcript

Feb 21, 2023 / 01:00PM GMT
Operator

Good day, and thank you for standing by. Welcome to the Sesen Bio and Carisma Therapeutics Fireside Chat. (Operator Instructions) Please be advised that today's call is being recorded.

I would now like to hand the conference over to your speaker today, Erin Clark, Vice President of Corporate Strategy and Investor Relations. Please go ahead.

Erin Clark - Sesen Bio, Inc. - VP of Corporate Strategy & IR

Thank you, and good morning, everyone. Joining me on today's call from the Sesen Bio team is Dr. Thomas Cannell, our President and Chief Executive Officer. From Carisma Therapeutics, we have Steven Kelly, Chief Executive Officer; and Dr. Michael Klichinsky, Co-Founder and Chief Scientific Officer.

I would like to remind you that today's discussion will include forward-looking statements related to the company's current plans and expectations, which are subject to risks and uncertainties. Actual results may differ materially due to various factors, including those described in Sesen Bio's most recent annual report on Form 10-K, quarterly

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot